29 Immune modulation and baseline biomarker correlation with clinical benefit following treatment with COM701+nivolumab+/-BMS-986207 in patients with platinum resistant ovarian cancer

• Yu Liang,
• Gady Cojocaru,
• Inbal Barbiro,
• Zurit Levine,
• Eran Ophir,
• Zoya Alteber,
• Pierre Ferre,
• Assaf Wool,
• Roy Granit,
• Adi Shuchami

Affiliations

Yu Liang

2Compugen USA Inc., South San Francisco, CA, USA

Gady Cojocaru

Greenberg Bladder Cancer Institute and Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland, USA

Inbal Barbiro

10Compugen Ltd., Holon, Israel

Zurit Levine

Aff1 grid.418916.3Compugen Ltd Tel Aviv Israel

Eran Ophir

10Compugen Ltd., Holon, Israel

Zoya Alteber

Aff38 grid.418916.30000000405064804Compugen Ltd Holon Israel

Pierre Ferre

7Compugen USA Inc., San Francisco, USA

Assaf Wool

Compugen Ltd., Holon, Israel

Roy Granit

1Compugen Ltd., Holon, Israel

Adi Shuchami

1Compugen Ltd., Holon, Israel